Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Am J Reprod Immunol ; 85(4): e13408, 2021 04.
Article in English | MEDLINE | ID: covidwho-1138076

ABSTRACT

PROBLEM: Lymphocyte immunotherapy (LIT) emerged in the early 1980s as a new therapeutic proposal for couples with a history of recurrent miscarriages (RM). However, in the early 2000s, the effectiveness of LIT was questioned. Recently, meta-analyses have observed the effectiveness and safety of LIT in treating couples with RM. Some studies evaluated the use of LIT in recurrent implantation failure (RIF) in in vitro fertilization cycles. METHODS: This systematic and narrative review evaluated the data available in the literature regarding the efficacy and safety of the use of LIT. Searches in PubMed/Medline, Embase, and Cochrane Library databases were conducted, using the following keywords: "recurrent miscarriage," "lymphocyte immunotherapy," and "recurrent implantation failure". RESULTS: This review describes the historical aspects of LIT and discusses its protocols, mechanisms of action, side effects, complications, and current evidence of the effectiveness in cases of reproductive failure. It also discusses the use of LIT during the COVID-19 pandemic and new immunological therapies. CONCLUSION: In the vast majority of studies, the use of LIT for RM couples has shown an improvement in pregnancy outcomes. The most of the current studies that support the evidence are quasi-experimental, with few randomized, double-blind studies (Level of evidence III). However, the current evidence are not convincing for the use of LIT in RIF patients.


Subject(s)
Abortion, Habitual/therapy , COVID-19 , Immunotherapy , Lymphocyte Transfusion , Lymphocytes , Pandemics , SARS-CoV-2 , Female , Humans , Pregnancy
2.
Transfusion ; 60(9): 1905-1909, 2020 09.
Article in English | MEDLINE | ID: covidwho-613577

ABSTRACT

New York is at the epicenter of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus. Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH) had to make changes to its cellular therapy operations to ensure patient, donor, and staff safety and well-being. In this article, we discuss the process changes we instituted for cellular therapy clinical care, collection, processing, and cryopreservation to cope with the rapidly evolving pandemic.


Subject(s)
Academic Medical Centers , COVID-19/epidemiology , Cell- and Tissue-Based Therapy/statistics & numerical data , Pandemics , SARS-CoV-2 , Academic Medical Centers/organization & administration , Academic Medical Centers/statistics & numerical data , Adult , Bone Marrow Transplantation/methods , Bone Marrow Transplantation/statistics & numerical data , COVID-19 Testing , Cell Separation/methods , Child , Clinical Trials as Topic/organization & administration , Cryopreservation/methods , Donor Selection , Humans , Immunotherapy, Adoptive/methods , Immunotherapy, Adoptive/statistics & numerical data , Lymphocyte Transfusion/methods , Lymphocyte Transfusion/statistics & numerical data , New York City/epidemiology , Organ Preservation/methods , Peripheral Blood Stem Cell Transplantation/methods , Peripheral Blood Stem Cell Transplantation/statistics & numerical data , Preservation, Biological/methods , Procedures and Techniques Utilization , Tissue Donors , Tissue and Organ Procurement/methods , Tissue and Organ Procurement/organization & administration
SELECTION OF CITATIONS
SEARCH DETAIL